A5052260087- Cervical Cancer and HPV Research
- Lymphoma Diagnosis and Treatment
- Genital Health and Disease
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Molecular Biology Techniques and Applications
- Reproductive tract infections research
- HER2/EGFR in Cancer Research
- CNS Lymphoma Diagnosis and Treatment
- Hepatitis B Virus Studies
- T-cell and Retrovirus Studies
- Bacteriophages and microbial interactions
- Cancer-related molecular mechanisms research
- Virus-based gene therapy research
- Cutaneous lymphoproliferative disorders research
- Endometrial and Cervical Cancer Treatments
- Plant Virus Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Virology and Viral Diseases
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Pancreatic function and diabetes
- Lung Cancer Research Studies
- Chromatin Remodeling and Cancer
Pfizer (United States)
2024-2025
Seagen (United States)
2019-2023
Maxygen (United States)
2022-2023
Queen Mary University of London
2003-2017
Cancer Research UK
2006-2010
Cancer Research Horizons
2003
University College London
1993-2002
World Cancer Research Fund International
2001
Institute of Molecular Medicine
1997
Whittington Hospital
1994
PURPOSE In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy combined either lenalidomide (Len) rituximab (R) has demonstrated efficacy acceptable safety. We evaluated the and safety of BV + Len R versus placebo in R/R DLBCL. METHODS ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing Patients received once every weeks, daily, weeks. The primary end point was overall survival...
Certain types of the human papilloma virus (HPV) are well established as primary cause cervical cancer. Several studies have shown that HPV testing can improve detection rate high-grade intraepithelial neoplasia (CIN), but these been carried out primarily in younger women. In this study we evaluated role an adjunct to cytology women aged 35 or over. An additional aim was evaluate commercially available kits for testing. A total 2988 eligible 34 more attending a routine smear 40 general...
The detection of high-risk human papillomavirus (HPV) DNA provides higher sensitivity but lower specificity than cytology for the identification high-grade cervical intraepithelial neoplasia (CIN). This study compared and several adjunctive tests CIN in a population referred to colposcopy because abnormal cytology.953 women participated study. Up seven were carried out on liquid PreservCyt sample: Hybrid Capture II (Digene), Amplicor (Roche), PreTect HPV-Proofer (NorChip), APTIMA HPV assay...
Women referred for colposcopy with mild and moderate dyskaryosis found to have only minor cervical abnormalities were screened oncogenic human papilloma virus (HPV) types. The natural development of these in 42 HPV-positive women was assessed by cytology at 6-month intervals up 2 years. As is the case cancers high-grade intra-epithelial neoplasia (CIN), frequently be associated HPV16, -18, -31 -33. Viral persistence lesions closely HPV16; 56% HPV16 isolates persistent compared 7% other HPV...
Several new assays have been developed for high-risk HPV testing of cervical samples; we compare six tests in a screening population. Residual material from liquid-based PreservCyt samples was assayed. Four (Hybrid Capture 2, Cobas, Abbott and Becton-Dickinson (BD)) measured DNA while two used RNA (APTIMA NorChip). Positivity rates ranged 13.4 to 16.3% the DNA-based with significantly lower positivity rate assay. The Gen-Probe APTIMA assay positive 10.3% women, which than all tests; NorChip...
High-risk human papillomavirus (HPV) DNA/RNA testing provides higher sensitivity but lower specificity than cytology for the identification of high-grade cervical intraepithelial neoplasia (CIN). Several new HPV tests are now available this purpose, and a direct comparison their properties is needed. Seven were evaluated with samples in liquid PreservCyt transport medium from 1,099 women referred colposcopy: Hybrid Capture 2 (Qiagen), Cobas (Roche), PreTect HPV-Proofer (NorChip), Aptima...
Cervical scrapes from 116 British women referred with cervical cancer were tested for the presence of high oncogenic risk human papillomavirus (HPV) genotypes (HPV(hr)). Ninety-four per cent had one or more these virus types and 66% HPV16-positive. HPV18 was frequent in adenocarcinoma. No evidence found an increased associated HPV16 E6 350G variant. The HLA DRB1* DQB1* alleles 155 normal cytology negative HPV(hr) DNA compared. DQB1*0301 alone (2P = 0.02) combination DRB1*0401 to be cancer....
Abstract Several studies have shown that HPV testing is substantially more sensitive than cytology for primary cervical screening. However, less data exist concerning the duration of protection afforded by a negative test compared to normal cytological outcome. Here we report long‐term findings from Hammersmith study in women aged 35 or more. Hybrid Capture II was performed on all available samples baseline screening visit. Passive surveillance subsequent results 2,982 undertaken using...
HR HPV genotypes when assayed collectively, achieve high sensitivity but low specificity for the prediction of CIN2+. Knowledge specific in an infection may facilitate use detection routine clinical practice.To compare rate and accuracy CIN2+ between PapType test (Genera Biosystems) other commercially available assays, to examine value full genotyping.PreservCyt samples from 1099 women referred abnormal cervical cytology were used. was chosen as primary end-point CIN3+ also evaluated. A...
A hybrid capture test that can be used to detect at least 13 high-risk HPV types (referred collectively as HPV-HR) in cervical scrapes (Hybrid Capture 2 probe set B, HC2-B) was evaluated. The HC2-B is accurate and highly reproducible the results obtained show excellent agreement with those by a multiplexed type-specific polymerase chain reaction (mts-PCR). An additional assay identify subset of HPV-HR may improve specificity without compromising sensitivity positive specimens result close...
Human papillomaviruses (HPV) play a causative role in the aetiology of cervical intra-epithelial neoplasia (CIN) and cancer. leukocyte antigens (HLA) are important regulation immune response to foreign antigens. The genetic variation at HLA class II loci (DR DQ) CIN (HPV 16, 18, 31 33 typed) was investigated by PCR DNA amplification oligonucleotide probe typing smears from British Caucasian patients (n = 176) controls 416). alleles DQBI*03, DRBI*04 DRBI*II were strongly associated with...
Several studies have shown that testing for high-risk human papillomavirus (HPV) types results in an improved sensitivity CIN2+, compared with cytology, although a somewhat lower specificity. We obtained follow-up results, at least one smear after participation the HART study, which HPV (HC-II) cytology as primary screening modality. With median of 6 years, 42 additional cases CIN2+ were identified; women who positive baseline more likely to develop than those negative (hazard ratio (HR)...
Abstract Background: Human papillomavirus (HPV) testing from clinician-collected cervical and self-collected cervico-vaginal samples is more sensitive for detecting CIN2+/CIN3+ than cytology-based screening, stimulating interest in HPV urine. The objective was to determine the performance of Trovagene test detection CIN2+ urine PreservCyt samples. Methods: Women referred colposcopy at St Mary's Hospital (London, United Kingdom), following abnormal cytology, were recruited this diagnostic...
Abstract HPV DNA testing is known to be much more sensitive than cytology, but less specific. A range of and related tests in 858 women referred for colposcopy because an abnormal smear were evaluated compare the performances these tests. This article compared Abbott test other which had been previously evaluated. was a real true 14 high‐risk types. The found highly cervical intraepithelial neoplasia grade 3 or worse (CIN3+) (98.9%) with specificity 31.5%. These numbers comparable Qiagen HC2...
To compare triage strategies using different human papillomavirus (HPV) consensus and genotyping tests a p16(INK4a) test.1228 women referred with borderline or single mildly dyskaryotic smear. Samples were taken at colposcopy PreservCyt. Tests included Hybrid Capture 2, Abbott RealTime PCR, BD HPV, Cobas 4800, PreTect HPV-Proofer, APTIMA p16(INK4a). Results based on the worst histology within 9 months.97/1228 (7.9%) had CIN3+ (203/1228 (17%) CIN2+). HPV testing alone 4800 sensitivity for...
High risk types of human papillomavirus (HR-HPV) play a major role in cervical cancer oncogenesis. This study aims to evaluate the efficacy HPV detection and typing as means identifying neoplasia high population. A management algorithm for implementation clinical practice is also proposed. nested case-control within cohort was undertaken Recife (Brazil). All 479 participants had scrapes collected followed by colposcopy. Samples were blindly analyzed polymerase chain reaction (PCR) typed...
Human papillomavirus (HPV) 16 and HPV18 E2 amino acid variants host HLA DR/DQ haplotypes have been identified by direct nucleic sequencing from cervical scrapes. HPV16 co-segregate with a nucleotide variant at nt350 (in E6), which previously has associated persistent infections. Both occur relatively more frequently in individuals 0401/0301 1101/0301 but are not related to lesion grade. Int. J. Cancer 73:651–655, 1997. © 1997 Wiley-Liss, Inc.